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The increasing importance of chemotherapy in
cancer management has resulted in the appearance
of several new agents but the problem of poor
selectivity and host toxicity still remains. Of these
newer agents doxorubicin has been widely tested
but its use and possibly its efficacy is limited by
cardiac toxicity. Several analogues of doxorubicin
have been produced in attempts to resolve this
problem. One of these, 4'epi-doxorubicin (4'epiDX),
has been shown to have less cardiac toxicity than
the parent compound (Natale et al., 1981; Casazza
et al., 1978). Its anti-tumour activity and plasma
kinetics in animals have also been reported by
several authors (Bonf4nte et al., 1979, 1980;
Casazza et al., 1978; Benjamin et al., 1977). Little
human data are available on this agent so this
study was designed to determine its distribution
and pharmacokinetics in patients.
Eight patients who were to be operated on for
proven disease received an i.v. bolus of 4'epiDX
(kindly supplied by Farmitalia Carlo Erba, Milan,
Italy) 2h before surgery. Four patients (Group A)
received 10mgm-2, 4 patients (Group B) received
20mgm-2 over 60-90sec, followed by 500ml
saline. Ninety min later, patients received 0.5mg
atropine sulphate and 10mg benzodiazepine i.m. in
preparation for a general anaesthetic after a further
30min.
Specimens were collected without interfering with
surgical procedures and small amounts of either
biopsy material or excised organs were immediately
frozen at -200. All tissues were examined by the
pathologist and collection time varied between 2-
4h depending upon the surgery. The HPLC method
of Moro et al. (1981) was modified to determine
the anthracycline concentration in tissues (Moro,
personal communication); 50ngml-1 4-demethoxy-
daunorubicin (Farmitalia-Carlo Erba) was used as
an internal standard in the homogenized specimen.
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The samples were homogenized in 5 or 10 parts of
distilled water-depending on the amount of tissue
available by Ultra-Turrax homogenizer. The
homogenates were adjusted to pH 8.4 with
phosphate buffer (0.1 M) and anthracyclines
extracted with chloroform-ethanol (8:2). After
binding with 0.3M phosphoric acid 4'epiDX was
further purified from organic contamination and
loaded onto a RP 18 column on a Perkin Elmer
HPLC. Samples were eluted with water-acetonitrile-
phosphoric acid (0.1 M) (40:40:20) and analysed on
a Perkin Elmer fluorimeter using an exciting
wavelength of 470nm and emission of 580nm. The
sensitivity of the method was 25ngg-1 tissue.
Forty-five specimens were obtained from the 8
patients with between 4 and 9 samples from each
patient. One specimen, an intercostal nerve
weighing only 60mg, proved too small to process.
The amounts of 4'epiDX found in the various
samples are shown in the Table. There was
considerable variation and in 4 samples from
patients receiving the lower dose 10mgm-2 (Group
A) no 4'epiDX was detectable. The concentration
of the drug in Group A ranged from 40ngg-1 in
subcutaneous fat to 996.5 ngg-1 in liver metastasis
and in Group B from 66.7ngg-1 in subcutaneous
fat to 1362.8 ngg 1 in a metastatic hilar lymph
node.
The various concentrations of 4'epiDX found in
normal tissue and in tumour material are shown in
the Figure. There is a suggestion of 3 concentration
ranges. A low amount, up to 181 ngg-1, was found
in subcutaneous fat, serosa, omentum, bronchus
(Group A) and subcutaneous fat, serosa, omentum,
spleen, ovary and vagina (Group B). An
intermediate level (216-615ngg-1) was found in
nerve, normal and cancerous lung and metastatic
lymph nodes (Group A) and in one muscle
specimen, normal stomach and stomach carcinoma,
normal endometrium and endometrial carcinoma,
oviduct, nerve and lymph node (Group B). High
concentrations (811-1363 ngg-1) were found in
normal lung and liver metastasis (Group A) and in
gallbladder, normal and neoplastic stomach tissues
and involved lymph nodes (Group B).
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Table 4'epiDX concentration (ngg-1) in human tissues after 10 or
20mgm-2 administration
Normal Neoplastic Normal Neoplastic
Tissue 1Omgm-2 20mgm-2
Subcutaneous fat 99.3 121.1
101.4 181.1
40.6 66.7
Muscle 125.4 345.4
125.5 144.8
Peritoneum 62.1 69.6
Omentum 147.9 173.9
69.4
Stomach 349.6 542.6
Spleen 175.5
Gallbladder 859.3
Ovary 156.7
Oviduct 405.2
Uterus 346.3 470
Vagina 176.3
Intercostal nerve 500.5 608.5
Lung 985.3 555.5 973.5 986
615.6
811.3 253.5 905.5
Bronchus 88
Lymph nodes 215.9 576.3 940.2
1362.8
Liver 996.5
(1362.8) No large differences were found in similar tissues
1000 * * 0 0in the 2 groups and a dose-response effect was
950 * observed only in muscles, lung cancer and lymph
nodes. At the higher dose (Group B) there was
900 - some evidence to suggest selective uptake by the
850 - tumour in comparison with the tissue of origin.
800 It has been shown that 4'epiDX disappears more
rapidly from serum than doxorubicin (Bonfante et
650 - al., 1979) and that between 2-4h after
600 . administration the circulating concentration is only
-10% of the peak 5-min value (Bonfante et al.,
C 550 1979; Benjamin et al., 1974). Very little is found in
0
500 * urine (Rosso et al., 1972), suggesting a rapid tissue
distribution similar to that of doxorubicin (Donelli
o 450 et al., 1979). C
° 400 - * Our results seem to confirm these findings and
are in agreement with the levels of 4'epiDX found 350- LA,
350 in animal tissues (Bonfante et al., 1979). The
H 300 primary excretion of anthracyclines appears to be
250 _ through hepatic metabolism and biliary clearance
(Benjamin et al., 1974; Broggini et al., 1980) and
200 - explains the high concentration of 4'epiDX in the
150 - r gallbladder 4.5h after administration, the only 00
* tissue in which the 13-OH metabolite has been 100 _ S .found.
50 - Since all the data presented here were obtained at
... times when the plasma concentration of 4'epiDX
10 20 10 20 would be expected to be very low and do not
Normal tissues Tumour appear to show significant dose-response
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relationships, the differences might represent
preferential tissue permeability. The low
concentrations of 4'epiDX found in fat, muscle,
serosa and spleen are in agreement with other
reports on anthracyclines (Chan et al., 1978;
Broggini et al., 1980) and may explain the low
haematological toxicity observed (Natale et al.,
1981). The level of 4'epiDX found in muscle was
less than that found for doxorubicin (Broggini et
al., 1980) and could explain the minor cardiac
toxicity.
In conclusion, it appears that the distribution of
anthracyclines is mainly due to blood flow and
hepatic clearance, in agreement with the literature.
Certain selective patterns are seen that cannot be
accounted for by vascularisation and there is some
evidence to suggest higher concentrations in tumour
tissue. The importance of minor metabolism and
the influence of necrotic material will need to be
determined before a more definite statement can be
made on the advantages of 4'epiDX over its parent
compound, doxorubicin.
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